Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult kidney transplant patients.
No known contraindications to Dipyridamole
Disqualifiers
Contraindications to Dipyridamole.
Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
Trial design
Design model
Parallel
Treatments tested in this trial
Dipyridamole 75 MG
DrugDipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.
Treatment groups
90 Participants
are divided into 2 treatment groupsGroup A: Treatment GroupExperimental treatment 1 intervention
Group B: Control GroupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Change in Serum Phosphorus Levels After Dipyridamole Administration
This study will evaluate the effectiveness of Dipyridamole in increasing serum phosphorus levels in kidney transplant recipients with hypophosphatemia.
Time frame
Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatioSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov